Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS AND VIEWS

Cancer cells remodel nuclear actin filaments to resist chemotherapy

Cancers that arise from epithelial cells often contain tumour cells that have acquired the characteristics of another cell type — a mesenchymal cell. A mouse model of skin cancer offers insights into why such cells resist treatment.
  1. Stephanie Panier

    1. Stephanie Panier is at the Max Planck Institute for Biology of Ageing and at the Institute for Genome Stability in Aging and Disease, Medical Faculty, University of Cologne, 50931 Cologne, Germany.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Modern therapeutic approaches for cancer, such as ‘targeted’ drugs or therapies that harness the immune system, have greatly advanced the treatment options for many types of tumour. However, chemotherapy failure is a key limiting factor in treatment success. Writing in Nature, Debaugnies et al.1 provide some reasons for why such treatment resistance can occur.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 616, 40-42 (2023)

doi: https://doi.org/10.1038/d41586-023-00801-y

References

  1. Debaugnies, M. et al. Nature 616, 168–175 (2023).

    Article  Google Scholar 

  2. Yang, J. et al. Nature Rev. Mol. Cell Biol. 21, 341–352 (2020).

    Article  PubMed  Google Scholar 

  3. Yeung, K. T. & Yang, J. Mol. Oncol. 11, 28–397 (2017).

    Article  PubMed  Google Scholar 

  4. De Las Rivas, J. et al. Arch. Toxicol. 95, 2279–2297 (2021).

    Article  PubMed  Google Scholar 

  5. Schmults, C. D. et al. J. Natl Compr. Cancer Netw. 19, 1382–1394 (2021).

    Article  Google Scholar 

  6. Cheung-Ong, K., Giaever, G. & Nislow, C. Chem. Biol. 20, 648–659 (2013).

    Article  PubMed  Google Scholar 

  7. Hodge, R. G. & Ridley, A. J. Nature Rev. Mol. Cell Biol. 17, 496–510 (2016).

    Article  PubMed  Google Scholar 

  8. Crosas-Molist, E. et al. Physiol. Rev. 102, 455–510 (2022).

    Article  PubMed  Google Scholar 

  9. Caridi, C. P., Plessner, M., Grosse, R. & Chiolo, I. Nature Cell Biol. 21, 1068–1077 (2019).

    Article  PubMed  Google Scholar 

  10. Lamm, N. et al. Nature Cell Biol. 22, 1460–1470 (2020).

    Article  PubMed  Google Scholar 

  11. Parisis, N. et al. EMBO J. 36, 3212–3231, (2017).

    Article  PubMed  Google Scholar 

  12. Ho, H. et al. Cancer Res. 72, 5516–5528 (2012).

    Article  PubMed  Google Scholar 

  13. Clayton, N. S. & Ridley, A. J. Front. Cell Dev. Biol. 8, 222 (2020).

    Article  PubMed  Google Scholar 

  14. Kim, C. et al. Cancer Cell 25, 102–117 (2014).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

The author declares no competing interests.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links